GlassScriptPhysician profile
Joseph Dejonckheere
NPI 1740276153
$3,390.09
in general payments reported to CMS, 2019-2025
23 companies · $1,508 in 2025
The $1,508 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $99.99 · 2022: $60.41 · 2023: $653 · 2024: $952 · 2025: $1,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,113.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $574.47 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $490.15 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $435.44 | 2024-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $330.05 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $283.88 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $170.21 | 2023-2025 | |
| Daiichi Sankyo INC. | $145.66 | 2023 | Injectafer |
| Vifor Pharma, INC. | $122.90 | 2023-2025 | Veltassa |
| Glaxosmithkline, LLC. | $122.76 | 2019-2025 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $99.30 | 2019-2024 | Velphoro |
| Amgen INC. | $93.05 | 2024-2025 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.55 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $77.75 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $69.22 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $56.51 | 2025 | Ozempic |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $47.27 | 2023-2025 | Strensiq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.05 | 2019-2024 | |
| Akebia Therapeutics INC | $35.83 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $32.62 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $31.30 | 2025 | |
| Ani Pharmaceuticals, INC. | $20.86 | 2024 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $18.11 | 2025 | |
| Opko Pharmaceuticals, LLC | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dejonckheere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.